Phase I study of GC1008 (fresolimumab): a human anti‐transforming growth factor‐beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In advanced cancers, transforming growth factor-beta (TGFβ) promotes tumor growth and metastases and suppresses host antitumor immunity. GC1008 is a human anti-TGFβ monoclonal antibody that neutralizes all isoforms of TGFβ. Here, the safety and activity of GC1008 was evaluated in patients with advanced malignant melanoma and renal cell carcinoma. METHODS: In this multi-center phase I trial, cohorts of patients with previously treated malignant melanoma or renal cell carcinoma received intravenous GC1008 at 0.1, 0.3, 1, 3, 10, or 15 mg/kg on days 0, 28, 42, and 56. Patients achieving at least stable disease were eligible to receive Extended Treatment consisting of 4 doses of GC1008 every 2 weeks for up to 2 additional courses. Pharmacokinetic and exploratory biomarker assessments were performed. RESULTS: Twenty-nine patients, 28 with malignant melanoma and 1 with renal cell carcinoma, were enrolled and treated, 22 in the dose-escalation part and 7 in a safety cohort expansion. No dose-limiting toxicity was observed, and the maximum dose, 15 mg/kg, was determined to be safe. The development of reversible cutaneous keratoacanthomas/squamous-cell carcinomas (4 patients) and hyperkeratosis was the major adverse event observed. One malignant melanoma patient achieved a partial response, and six had stable disease with a median progression-free survival of 24 weeks for these 7 patients (range, 16.4-44.4 weeks). CONCLUSIONS: GC1008 had no dose-limiting toxicity up to 15 mg/kg. In patients with advanced malignant melanoma and renal cell carcinoma, multiple doses of GC1008 demonstrated acceptable safety and preliminary evidence of antitumor activity, warranting further studies of single agent and combination treatments. TRIAL REGISTRATION: Clinicaltrials.gov NCT00356460.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Fresolimumab, a human monoclonal antibody against TGF‐β in a phase 1 clinical trial (NCT00356460), demonstrated preliminary evidence of anti‐tumor activity in malignant melanoma and renal cell carcinoma [42].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [42]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · cited 4×
“Recently, targeted therapies directed against B-RAF and other genes have been used successfully to treat patients with MM [33].”
BackgroundInfluentialMassagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907
Tumor Self-Seeding by Circulating Cancer Cells
Kim, M.-Y., Oskarsson, T., Acharyya, S., Nguyen, D. X., Zhang, X. H.-F., Norton, L., & Massagué, J. (2009) · Cell · doi:10.1016/j.cell.2009.11.025 · Cited by 1,335 · cited 1×
“Norton and Massague [48,49] have proposed that cancer cell migration and ‘‘re-seeding’’ of the primary tumor with cells primed for metastatic growth leads to a tumor with heterogenous subpopulations of aggressive, rapidly growing cancer cells that may become resistant to treatment.”
BackgroundRAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Su, F., Viros, A., Milagre, C., Trunzer, K., Bollag, G., Spleiss, O., Reis-Filho, J. S., Kong, X., Koya, R. C., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105358 · Cited by 1,038
TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4
Padua, D., Zhang, X. H.-F., Wang, Q., Nadal, C., Gerald, W. L., Gomis, R. R., & Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.01.046 · Cited by 952
Roberts, A. B., Anzano, M. A., Lamb, L. C., Smith, J. M., & Sporn, M. B. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.9.5339 · Cited by 919 · cited 1×
“Transforming growth factor-beta (TGFb) is a pleiotropic cytokine that is a member of a superfamily of ligands that includes bone morphogenetic proteins and activins [1,2].”
BackgroundKorn, E. L., Liu, P.-Y., Lee, S. J., Chapman, J.-A. W., Niedzwiecki, D., Suman, V. J., Moon, J., Sondak, V. K., Atkins, M. B., Eisenhauer, E. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.7837 · Cited by 705
Terabe, M., Matsui, S., Park, J.-M., Mamura, M., Noben-Trauth, N., Donaldson, D. D., Chen, W., Wahl, S. M., Ledbetter, S., Pratt, B., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022227 · Cited by 539
Self-citationTransforming Growth Factor-β and the Immune Response: Implications for Anticancer Therapy
Wrzesinski, S. H., Wan, Y. Y., & Flavell, R. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1157 · Cited by 452 · cited 2×
“With broad activity in natural killer (NK) cells, T cells including T regulatory cells, NKT cells, monocytes/ macrophages, and dendritic cells, TGFb can down-regulate both primary and secondary immune responses and suppress antitumor effector cells [3,11,12].”
Background
Cited by
Items 101–200 of 508
A New Switch for TGFβ in Cancer
Yeh, H.-W., Lee, S.-S., Chang, C.-Y., Lang, Y.-D., & Jou, Y.-S. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2019 · Cited by 106
Osteogenesis Imperfecta: Current and Prospective Therapies
Botor, M., Fus-Kujawa, A., Uroczynska, M., Stępień, K., Galicka, A., Gawron, K., & Sieroń, A. L. (2021) · Biomolecules · doi:10.3390/biom11101493 · Cited by 144
“Another drug, Fresolimumab, a GC1008 antibody that inhibits TGF-β, previously used to treat cancer patients [42], is currently in clinical trials to verify its safety and efficacy in the treatment of OI in adult patients [28,39].”
MethodRole of TGF-β in metastatic colon cancer: it is finally time for targeted therapy
Villalba-Esparza, M., Evans, S. R., Vidal‐Vanaclocha, F., & Calvo, A. (2017) · Cell and Tissue Research · doi:10.1007/s00441-017-2633-9 · Cited by 111
“It is currently in phase I clinical trials for renal cell diseases, including carcinoma (Morris et al. 2014).”
BackgroundTang, Y., Durand, S., Dalle, S., & Caramel, J. (2020) · Cancers · doi:10.3390/cancers12082154 · Cited by 124
“TGFβ pathway inhibitors [91] TGFβ monoclonal antibody GC1008 (fresolimumab) Phase I NCT00356460 Renal Cell Carcinoma and Malignant Melanoma”
BackgroundZhang, J., Hu, Z., Horta, C. A., & Yang, J. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.002 · Cited by 114
Tolcher, A. W., Berlin, J. D., Cosaert, J., Kauh, J., Chan, E., Piha-Paul, S. A., Amaya, A., Tang, S., Driscoll, K., Kimbung, R., et al. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3245-5 · Cited by 105
Targeting TGF-β for treatment of osteogenesis imperfecta
Song, I.-W., Nagamani, S. C. S., Nguyen, D., Grafe, I., Sutton, V. R., Gannon, F. H., Munivez, E., Jiang, M., Tran, A., Wallace, M. J., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci152571 · Cited by 107
TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET
den Hollander, M. W., Bensch, F., Glaudemans, A. W. J. M., Munnink, T. H. O., Enting, R. H., den Dunnen, W. F. A., Heesters, M. A. A. M., Kruyt, F. A. E., Hooge, M. N. L., de Groot, J. C., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.154401 · Cited by 110
“In a phase 1 study with fresolimumab in patients with melanoma and renal cell carcinoma, six patients achieved stable disease and one patient had a partial response (10).”
BackgroundBiology of Radiation-Induced Lung Injury
Roy, S., Salerno, K. E., & Citrin, D. E. (2021) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2020.11.006 · Cited by 112
Zalfa, C., & Paust, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.633205 · Cited by 107
The role of TGF-β in bone metastasis: novel therapeutic perspectives
Buijs, J. T., Stayrook, K. R., & Guise, T. A. (2012) · BoneKEy Reports · doi:10.1038/bonekey.2012.96 · Cited by 96
Zhang, F., Dong, W., Zeng, W., Zhang, L., Zhang, C., Qiu, Y., Wang, L., Yin, X., Zhang, C., & Liang, W. P. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0698-0 · Cited by 104
The TGF-β Pathway: A Pharmacological Target in Hepatocellular Carcinoma?
Gonzalez‐Sanchez, E., Vaquero, J., Fernández‐Barrena, M. G., Lasarte, J. J., Avila, M. A., Sarobe, P., Reig, M., Calvo, M., & Fabregat, I. (2021) · Cancers · doi:10.3390/cancers13133248 · Cited by 110
Epithelial to Mesenchymal Transition in a Clinical Perspective
Pasquier, J., Abu-Kaoud, N., Thani, H. A., & Rafii, A. (2015) · Journal of Oncology · doi:10.1155/2015/792182 · Cited by 103
Rodriguez-Ruiz, M. E., Rodríguez, I., Mayorga, L., Labiano, T., Barbés, B., Etxeberría, I., Ponz‐Sarvisé, M., Azpilikueta, A., Bolaños, E., Sanmamed, M. F., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0558 · Cited by 99
“Many strategies have been followed (30), but neutralizing mAbs such as fresolizumab and small-molecule inhibitors of SMAD2/3 phosphorylation are the most advanced options under current clinical development (31, 32).”
BackgroundTGFβ-Directed Therapeutics: 2020
Teicher, B. A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107666 · Cited by 109
TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
Yi, M., Li, T., Niu, M., Wu, Y., Zhao, Z., & Wu, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1061394 · Cited by 102
The Role of TGF-β in Bone Metastases
Trivedi, T., Pagnotti, G. M., Guise, T. A., & Mohammad, K. S. (2021) · Biomolecules · doi:10.3390/biom11111643 · Cited by 108
Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics
Le, B. T., Raguraman, P., Kosbar, T. R., Fletcher, S., Wilton, S. D., & Veedu, R. N. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.11.007 · Cited by 97
Cao, Z., Quazi, S., Arora, S., Osellame, L. D., Burvenich, I. J. G., Janes, P. W., & Scott, A. M. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-024-01099-2 · Cited by 100
Terabe, M., Robertson, F. C., Clark, K., De Ravin, E., Bloom, A., Venzon, D. J., Kato, S., Mirza, A., & Berzofsky, J. A. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1308616 · Cited by 89
“an anti-TGF-b mAb that neutralizes all isoforms, was reported to have signs of antitumor effects in some patients.(25) With the”
BackgroundSelf-citationTransforming growth factor β signaling pathway: A promising therapeutic target for cancer
Chen, Y., Di, C., Zhang, X., Wang, J., Wang, F., Yan, J., Xu, C., Zhang, J., Zhang, Q., Li, H., et al. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29108 · Cited by 93
Insights into the Transforming Growth Factor-β Signaling Pathway in Cutaneous Melanoma
Perrot, C. Y., Javelaud, D., & Mauviel, A. (2013) · Annals of Dermatology · doi:10.5021/ad.2013.25.2.135 · Cited by 101
Stevenson, J. P., Kindler, H. L., Papasavvas, E., Sun, J., Jacobs-Small, M., Hull, J., Schwed, D., Ranganathan, A., Newick, K., Heitjan, D. F., et al. (2013) · OncoImmunology · doi:10.4161/onci.26218 · Cited by 85
Nanoceria as a possible agent for the management of COVID-19
Allawadhi, P., Khurana, A., Allwadhi, S., Joshi, K., Packirisamy, G., & Bharani, K. K. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100982 · Cited by 85
Druggable genome and precision medicine in cancer: current challenges
Dupont, C., Riegel, K., Pompaiah, M., Juhl, H. H., & Rajalingam, K. (2021) · FEBS Journal · doi:10.1111/febs.15788 · Cited by 86
Blockade of TGF‐β enhances tumor vaccine efficacy mediated by CD8+ T cells
Takaku, S., Terabe, M., Ambrosino, E., Peng, J., Lonning, S., McPherson, J. M., & Berzofsky, J. A. (2010) · International Journal of Cancer · doi:10.1002/ijc.24961 · Cited by 81
Self-citationConnolly, E. C., Saunier, E. F., Quigley, D., Luu, M. T., De Sapio, A., Hann, B., Yingling, J. M., & Akhurst, R. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2941 · Cited by 82
Immune checkpoint inhibitors: therapeutic advances in melanoma.
Márquez‐Rodas, I., Cerezuela-Fuentes, P., Soria, A., Berrocal, A., Riso, A. A., González‐Cao, M., & Martín‐Algarra, S. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.10.27 · Cited by 93
“It demonstrated acceptable safety and an objective response in a melanoma patient (80).”
BackgroundPromising Therapy Candidates for Liver Fibrosis
Wang, P., Koyama, Y., Liu, X., Xu, J., Ma, H.-Y., Liang, S., Kim, I. H., Brenner, D. A., & Kisseleva, T. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00047 · Cited by 81
“In patients with advanced malignant melanoma and renal cell carcinoma, fresolimumab demonstrated acceptable safety and preliminary evidence of antitumor activity (Trachtman et al., 2011; Morris et al., 2014; Lacouture et al., 2015).”
BackgroundTabe, Y., Shi, Y. X., Zeng, Z., Jin, L., Shikami, M., Hatanaka, Y., Miida, T., Hsu, F. J., Andreeff, M., & Konopleva, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062785 · Cited by 78
Self-citationGu, S., & Feng, X. (2018) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmy092 · Cited by 84
“Fresolimumab has shown partial and stable response in a phase I study of advanced melanoma [105].”
BackgroundRational targeting of immunosuppressive neutrophils in cancer
Zhao, Y., Rahmy, S., Liu, Z., Zhang, C., & Lü, X. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107556 · Cited by 80
Therapeutic strategies to remodel immunologically cold tumors
Wang, M., Wang, S., Desai, J., Trapani, J. A., & Neeson, P. J. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1226 · Cited by 88
“The most extensively studied antibody, fresolimumab (GC1008), which sequesters all isoforms of TGF-b, has also progressed to clinical trials.(107) However, both small molecules and antibodies have had little clinical impact.”
BackgroundTGFβ signaling networks in ovarian cancer progression and plasticity
Kumari, A., Shonibare, Z., Monavarian, M., Arend, R. C., Lee, N. Y., Inman, G. J., & Mythreye, K. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10077-z · Cited by 81
“Fresolimumab ([255] (Sanofi, GC1008) is a high affinity Fig.”
BackgroundTGF-β in the Bone Microenvironment: Role in Breast Cancer Metastases
Buijs, J. T., Stayrook, K. R., & Guise, T. A. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0075-6 · Cited by 89
Trial Watch: Immunotherapy plus radiation therapy for oncological indications
Vacchelli, E., Bloy, N., Aranda, F., Buqué, A., Cremer, I., Demaria, S., Eggermont, A., Formenti, S. C., Fridman, W. H., Fucikova, J., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1214790 · Cited by 76
Microenvironmental regulation of solid tumour resistance to CAR T cell therapy
Lamplugh, Z. L., Wellhausen, N., June, C. H., & Fan, Y. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01229-3 · Cited by 87
Neutrophil-derived granule cargoes: paving the way for tumor growth and progression
Rawat, K., Syeda, S., & Shrivastava, A. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09951-1 · Cited by 90
Response and Resistance to RAS Inhibition in Cancer
Ebright, R. Y., Dilly, J., Shaw, A. T., & Aguirre, A. J. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0349 · Cited by 83
Reverting Immune Suppression to Enhance Cancer Immunotherapy
Guerrouahen, B. S., Maccalli, C., Cugno, C., Rutella, S., & Akporiaye, E. T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01554 · Cited by 77
The TGF-β Family in Glioblastoma
Cancela, I. G., & Caja, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021067 · Cited by 78
“Many research projects focus on solving this problem and proposing new therapeutic targets, including molecules related to TGF-β (Table 1).”
BackgroundEvolution of phage display technology: from discovery to application
Rahbarnia, L., Farajnia, S., Babaei, H., Majidi, J., Veisi, K., Ahmadzadeh, V., & Akbari, B. (2016) · Journal of drug targeting · doi:10.1080/1061186x.2016.1258570 · Cited by 73
“Belimumab (BenlystaR ) IgG1 B-Lyse Systemic lupus erythematosus Approved [30] Adalimumab (HumiraR ) IgG1 TNF-a Rheumatic arthritis, Crohn’s disease, psoriasis arthritis Approved [31] Necitumumab (IMC-11F8) IgG1 EGFR Colorectal cancer Phase II [32] Raxibacumab (ABtraxT) IgG1 PA Anthrax Phase I [33] MOR103 IgG1 GM-CSF R…”
BackgroundMatrix Stiffness and Colorectal Cancer
Liu, C., Pei, H., & Tan, F. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s231010 · Cited by 74
The Role of TGF-β Signaling Pathways in Cancer and Its Potential as a Therapeutic Target
Yang, Y., Ye, W.-L., Zhang, R., He, X., Wang, J., Liu, Y., Wang, Y., Yang, X., Zhang, Y., & Gan, W.-J. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/6675208 · Cited by 86
“Phase I studies have shown that GC1008 has significant antitumor activity in patients with advanced malignant melanoma and renal cell carcinoma [165].”
BackgroundStrategies for developing and optimizing cancer vaccines
Maeng, H. M., & Berzofsky, J. A. (2019) · F1000Research · doi:10.12688/f1000research.18693.1 · Cited by 68
Self-citationTumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy
Tschernia, N. P., & Gulley, J. L. (2022) · BioDrugs · doi:10.1007/s40259-022-00521-1 · Cited by 64
Neutrophils at the Crossroads: Unraveling the Multifaceted Role in the Tumor Microenvironment
Awasthi, D., & Sarode, A. Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052929 · Cited by 71
“…that exploits the tumor-killing ability of neutrophils is using TGF-β -blocking antibodies either as monotherapy or as combination therapy with [191] fresolimumab, which has been shown to be used in patients with melanoma [192], renal cell carcinoma [193], and metastatic breast cancer [194].”
BackgroundHow Signaling Molecules Regulate Tumor Microenvironment: Parallels to Wound Repair
Gál, P., Varinská, L., Fáber, L., Novak, S., Szabó, P., Mitrengová, P., Miroššay, A., Mučaji, P., & Smetana, K. (2017) · Molecules · doi:10.3390/molecules22111818 · Cited by 62
“TGF-β ligand inhibitors Fresolimumab (GC1008) (human anti-TGF-β monoclonal antibody) [33]”
BackgroundEffect of Anti-TGF-β Treatment in a Mouse Model of Severe Osteogenesis Imperfecta
Tauer, J. T., Abdullah, S., & Rauch, F. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3617 · Cited by 60
“Clinical studies with the human TGF-b monoclonal antibody Fresolimumab reported in about 14% of the patients gingival bleeding as a treatmentemergent adverse event.((28,29)) However, our observation might be strain related because no 1D11-associated side effects or deaths were reported in Crtap and þ/G610C mice or the…”
BackgroundExploring TGF-β Signaling in Cancer Progression: Prospects and Therapeutic Strategies
Sheikh, K., Amjad, M., Irfan, M., Anjum, S., Majeed, T., Riaz, M. U., Jassim, A. Y., Sharif, E., & Ibrahim, W. N. (2025) · OncoTargets and Therapy · doi:10.2147/ott.s493643 · Cited by 69
TGF-β signaling pathway: Therapeutic targeting and potential for anti-cancer immunity
Ali, S., Rehman, M. U., Yatoo, A. M., Arafah, A. M., Khan, A., Rashid, S., Majid, S., Ali, A., & Ali, M. N. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175678 · Cited by 64
Inflammatory Networks in Renal Cell Carcinoma
Kruk, L., Mamtimin, M., Braun, A., Anders, H., Andrassy, J., Gudermann, T. W., & Mammadova‐Bach, E. (2023) · Cancers · doi:10.3390/cancers15082212 · Cited by 64
Greco, R., Qu, H., Qu, H., Theilhaber, J., Shapiro, G., Gregory, R., Winter, C., Malkova, N., Sun, F., Jaworski, J., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1811605 · Cited by 58
“Its predecessor, fresolimumab, has been evaluated in several indications in the clinic.(28,56)”
BackgroundSelf-citationThe role of matrix stiffness in cancer stromal cell fate and targeting therapeutic strategies
Wei, J., Yao, J., Yan, M., Xie, Y., Liu, P., Mao, Y., & Li, X. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.08.005 · Cited by 55
Drug Development for Metastasis Prevention
Fontebasso, Y., & Dubinett, S. M. (2015) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v20.i5-6.150 · Cited by 66
Yoo, C., Javle, M. M., Mata, H. V., de Braud, F., Trojan, J., Raoul, J., Kim, J. W., Ueno, M., Lee, C., Hijioka, S., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000365 · Cited by 61
“Other TGF-β pathway targeting agents (eg, fresolimumab, an antibody that can bind TGF-β1, TGF-β2, and TGFβ3) have also exhibited actinic keratosis, hyperkeratosis, keratoacanthoma, basal cell carcinoma, and squamous cell carcinoma as dermatological AEs, indicating that these events are associated with inhibition of th…”
TGF-β Signaling in Cancer: Mechanisms of Progression and Therapeutic Targets
Cecerska‐Heryć, E., Jerzyk, A., Goszka, M., Polikowska, A., Rachwalska, J., Serwin, N. M., Wojciuk, B., & Dołęgowska, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157326 · Cited by 72
The molecular biology of pelvi-ureteric junction obstruction
Jackson, L., Woodward, M. N., & Coward, R. J. (2017) · Pediatric Nephrology · doi:10.1007/s00467-017-3629-0 · Cited by 64
Danielpour, D. (2024) · Pharmaceuticals · doi:10.3390/ph17040533 · Cited by 65
Safer approaches to therapeutic modulation of TGF-β signaling for respiratory disease
Lachapelle, P., Li, M., Douglass, J. A., & Stewart, A. G. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.010 · Cited by 56
“Frequent toxicities included nausea, bleeding, and benign and malignant skin neoplasms with grade 3/4 AEs reported in 23–67% of patients (den Hollander et al., 2015; Morris et al., 2014; Stevenson et al., 2013).”
BackgroundBaseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients
Formenti, S. C., Hawtin, R. E., Dixit, N., Evensen, E., Lee, P., Goldberg, J. D., Li, X., Vanpouille-Box, C., Schaue, D., McBride, W. H., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0633-x · Cited by 53
Kaminska, B., & Cyranowski, S. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-30651-9_9 · Cited by 57
TGF‐β signaling in liver metastasis
Marvin, D. L., Heijboer, R., ten Dijke, P., & Ritsma, L. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.160 · Cited by 57
Matters of context guide future research in TGFβ superfamily signaling
Akhurst, R. J., & Padgett, R. W. (2015) · Science Signaling · doi:10.1126/scisignal.aad0416 · Cited by 52
“However, phase 1 clinical trials of anti-ligand antibodies and small-molecule receptor kinase inhibitors have not shown severe adverse effects (93, 94).”
BackgroundChruścik, A., Gopalan, V., & Lam, A. K.-Y. (2017) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2017.11.001 · Cited by 56
Blockade of TGF-β signaling: a potential target for cancer immunotherapy?
Ungefroren, H. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1636034 · Cited by 50
Takahashi, K., Akatsu, Y., Podyma‐Inoue, K. A., Matsumoto, T., Takahashi, H., Yoshimatsu, Y., Koinuma, D., Shirouzu, M., Miyazono, K., & Watabe, T. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.012492 · Cited by 56
Abnormal signal pathways and tumor heterogeneity in osteosarcoma
Sun, Y., Zhang, C., Fang, Q., Zhang, W., & Liu, W. Y. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-03961-7 · Cited by 55
Recent advances in the role of Th17/Treg cells in tumor immunity and tumor therapy
Qianmei, Y., Su, Z., Wang, G., Li, H., & Lian, G. (2021) · Immunologic Research · doi:10.1007/s12026-021-09211-6 · Cited by 56
“Fresolimumab (GC1008) [122] and AP12009 [123] are inhibitors of TGF-β and have been used in clinical trials as targeted drugs for TGF-β.”
MethodTrial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy
Buqué, A., Bloy, N., Aranda, F., Cremer, I., Eggermont, A. M. M., Fridman, W. H., Fucikova, J. P., Galon, J., Špíšek, R., Tartour, É., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1149674 · Cited by 51
Cancer-associated fibroblasts as target and tool in cancer therapeutics and diagnostics
Vlieghere, E. D., Verset, L., Demetter, P., Bracke, M., & Wever, O. D. (2015) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-015-1818-4 · Cited by 57
“Fresolimumab a monoclonal antibody against TGF-β has been tested in clinical trials for melanoma, renal cell carcinoma, mesothelioma and in combinational therapy for metastatic breast cancer [38, 74].”
MethodMrad, M., Imbert, C., Garcia, V., Rambow, F., Therville, N., Carpentier, S., Ségui, B., Levade, T., Azar, R., Marine, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12380 · Cited by 52
Recent Advances in the Development of TGF-β Signaling Inhibitors for Anticancer Therapy
Lee, H.-J. (2020) · Journal of Cancer Prevention · doi:10.15430/jcp.2020.25.4.213 · Cited by 51
“Fresolimumab (GC-1008) is a human pan TGF-β neutralizing mAb that was evaluated in clinical studies in patients with advanced solid tumors, including melanoma, renal, and squamous cell carcinoma [55,56].”
BackgroundBiomarkers and Immunotherapeutic Targets in Glioblastoma
Hung, A. L., Garzón-Muvdi, T., & Lim, M. K. (2017) · World Neurosurgery · doi:10.1016/j.wneu.2017.03.011 · Cited by 53
Heart failure as interstitial cancer: emergence of a malignant fibroblast phenotype
Oatmen, K. E., Cull, E. H., & Spinale, F. G. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0286-y · Cited by 52
Jena, B. C., Das, C. K., Banerjee, I., Das, S., Bharadwaj, D., Majumder, R., & Mandal, M. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114474 · Cited by 53
Strategies to Use Immune Modulators in Therapeutic Vaccines Against Cancer
Berzofsky, J. A., Terabe, M., & Wood, L. V. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.02.002 · Cited by 50
Self-citationAnti-Cancer Stem-like Cell Compounds in Clinical Development – An Overview and Critical Appraisal
Marcucci, F., Rumio, C., & Lefoulon, F. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00115 · Cited by 51
Nyman, J. S., Merkel, A. R., Uppuganti, S., Nayak, B., Rowland, B. J., Makowski, A. J., Oyajobi, B. O., & Sterling, J. A. R. (2016) · Bone · doi:10.1016/j.bone.2016.07.007 · Cited by 50
Cook, L. M., Araujo, A., Pow‐Sang, J. M., Budzevich, M. M., Basanta, D., & Lynch, C. C. (2016) · Scientific Reports · doi:10.1038/srep29384 · Cited by 48
Fattore, L., Cafaro, G., Martile, M. D., Campani, V., Sacconi, A., Liguoro, D., Marra, E., Bruschini, S., Stoppoloni, D., Cirombella, R., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02547-9 · Cited by 55
“Along the same line, a mAb targeting TGFβ1 receptor, namely Fresolimumab showed promising results in a phase I trial involving patients with melanoma [57].”
BackgroundDantonio, P. M., Klein, M., Freire, M. R. V. B., Araujo, C. D. N., Chiacetti, A. C., & Correa, R. G. (2018) · Bioscience Reports · doi:10.1042/bsr20180511 · Cited by 52
Microbiota Modulation of Myeloid Cells in Cancer Therapy
Goldszmid, R. S., Dzutsev, A., Viaud, S., Zitvogel, L., Restifo, N. P., & Trinchieri, G. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0225 · Cited by 46
Khoshakhlagh, M., Soleimani, A., Binabaj, M. M., Avan, A., Ferns, G. A., Khazaei, M., & Hassanian, S. M. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.03.031 · Cited by 49
Tewari, D., Priya, A., Bishayee, A., & Bishayee, A. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.795 · Cited by 46
Transforming growth factor-β in tumour development
Trelford, C. B., Dagnino, L., & Guglielmo, G. M. D. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.991612 · Cited by 49
“As for neutralizing antibodies, Fresolimumab, a pan TGFβ human monoclonal antibody, is in clinical trials for malignant melanoma (Morris et al., 2014).”
BackgroundEpithelial-to-Mesenchymal Transition in the Pathogenesis and Therapy of Head and Neck Cancer
Thierauf, J., Veit, J. A., & Heß, J. (2017) · Cancers · doi:10.3390/cancers9070076 · Cited by 45
“TWIST1 Helix-loop-helix transcription factor, plays an essential and pivotal role in multiple stages of embryonic development Promotes the formation of cancer stem cells and EMT, targeting TWIST1-related molecules significantly inhibits tumor growth and thus improves the survival of cancer patients [21]”
BackgroundResisting Resistance to Immune Checkpoint Therapy: A Systematic Review
Haibe, Y., Husseini, Z. E., Sayed, R. E., & Shamseddine, A. I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176176 · Cited by 47
“Additionally, GC1008 (Fresolimumab) is an anti-TGF-β human monoclonal antibody that was tested in a phase I trial for safety in patients with melanoma and renal cell carcinoma [105].”
BackgroundThe role of the immune system in neurofibromatosis type 1-associated nervous system tumors
Karmakar, S., & Reilly, K. M. (2016) · CNS Oncology · doi:10.2217/cns-2016-0024 · Cited by 44
TGF-β Signaling in Gastrointestinal Cancers: Progress in Basic and Clinical Research
Yokobori, T., & Nishiyama, M. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6010011 · Cited by 45
“For instance, GC1008—an anti-TGF-β monoclonal antibody—induced the formation of cutaneous tumors including keratoacanthoma, squamous-cell carcinomas, and hyperkeratosis [62].”
BackgroundLöffek, S. (2018) · Journal of Oncology · doi:10.1155/2018/9732939 · Cited by 49
The Multifaceted Role of TGF-β in Gastrointestinal Tumors
Sabbadini, F., Bertolini, M., Matteis, S. D., Mangiameli, D., Contarelli, S., Pietrobono, S., & Melisi, D. (2021) · Cancers · doi:10.3390/cancers13163960 · Cited by 48
COHN, A., LAHN, M. M., WILLIAMS, K. E., CLEVERLY, A. L., PITOU, C., KADAM, S. K., FARMEN, M. W., DESAIAH, D., RAJU, R., CONKLING, P., et al. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2679 · Cited by 43
Importance of carcinoma-associated fibroblast-derived proteins in clinical oncology
Valcz, G., Sipos, F., Tulassay, Z., Molnar, B., & Yagi, Y. (2014) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2014-202561 · Cited by 39
Roles of immune microenvironment heterogeneity in therapy-associated biomarkers in lung cancer
Wang, L., Zhu, B., Zhang, M., & Wang, X. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.09.008 · Cited by 45
Aberrant TGF-β activation in bone tendon insertion induces enthesopathy-like disease
Wang, X., Xie, L., Crane, J. L., Zhen, G., Li, F., Yang, P., Gao, M., Deng, R., Wang, Y., Jia, X., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96186 · Cited by 76
Azzam, M., Elsafy, S., Abdelgelil, S. A., Weiskirchen, R., Asimakopoulou, A., Lorenzi, F. D., Lammers, T., Mansour, S., & Tammam, S. N. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12060590 · Cited by 43
Arjaans, M., Munnink, T. H. O., Timmer‐Bosscha, H., Reiß, M., Walenkamp, A., Hooge, M. N. L., de Vries, E. G. E., & Schroder, C. P. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.05.001 · Cited by 49
Bedinger, D., Lao, L., Khan, S., Lee, S., Takeuchi, T., & Mirza, A. M. (2016) · mAbs · doi:10.1080/19420862.2015.1115166 · Cited by 42
Metadata
- Authors
- Morris, J. C., Tan, A. R., Olencki, T. E., Shapiro, G. I., Dezube, B. J., Reiss, M., Hsu, F. J., Berzofsky, J. A., & Lawrence, D. P.
- Affiliations
- National Cancer Institute (US)
- Rutgers Cancer Institute (US)
- The Ohio State University (US)
- Dana-Farber Cancer Institute (US)
- Beth Israel Deaconess Medical Center (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Morris, John C.
- Berzofsky, Jay A.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-03-11
- Volume
- 9
- Issue
- 3
- Pages
- e90353
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3949712
- OpenAlex
- W2075873658
- Cited by
- 487
- References
- 50
- Citations by year
- 2026: 29 · 2025: 39 · 2024: 48 · 2023: 47 · 2022: 36 · 2021: 46 · 2020: 49 · 2019: 30 · 2018: 29 · 2017: 41 · 2016: 30 · 2015: 29 · 2014: 9
- FWCI
- 14.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Massachusetts General Hospital
- Ohio State University
- Rutgers Cancer Institute of New Jersey
- National Institutes of Health
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- TGF-beta, melanoma, renal cell carcinoma, advanced cancer, dose escalation, safety, pharmacokinetics, keratoacanthoma, squamous cell carcinoma, anticancer activity, progression-free survival
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Melanoma, Middle Aged, Neoplasm Staging, Tomography, X-Ray Computed, Transforming Growth Factor beta, Treatment Outcome, Positron-Emission Tomography, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.